Highest-materiality recent filing
Ardent Health Q1 2026: Revenue $1.60B (+7%), Adjusted EBITDA $124M (+26%), Reaffirms FY Guidance
Total revenue $1.602B (+7.0% YoY); net income $40M ($0.28 diluted EPS) vs $41M ($0.29) a year ago.
Ardent Health Q4 adj EBITDA down 26.6% to $134M; 2026 guidance issued
Q4 total revenue $1.605B (flat YoY); net income $45M vs $114M prior year.
Ardent Health authorizes $50M share repurchase program; $609M cash on hand
Board authorized up to $50M in common stock repurchases; no expiration date.
Ardent Health Q3 net loss $23M; cuts 2025 adj. EBITDA guidance to $530-555M
Revenue $1.58B (+8.8% YoY); net loss attributable of $23M vs net income $26M in Q3 2024.
Ardent Health amends $777.5M term loan facility; rate cut 50 bps, maturity extended to 2032
Interest rate reduced by 50 bps to Term SOFR + 2.25%; expected annual interest savings of ~$3.9M.
Ardent Health Q2 revenue up 12% to $1.65B; Adj EBITDA +39% to $170M; reaffirms FY25 guidance
Net income $73M ($0.52 diluted EPS) vs $43M ($0.34) prior year; adjusted EBITDA $170M.
On June 16, 2025, Ardent Health, Inc. (the “Company”) and David Schultz determined that Mr. Schultz would no longer serve as President, Hospital Operations and would depart the Company effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event earnings